Dec 6, 2024
11:30am - 12:00pm
Hynes, Level 2, Room 200
Nazmiye Yapici1,2,Estelle Chiari2,Xiuling Liu1,2,Catherine Pilon2,Daniel Gibbs2,Rodney Oakley2,Dongyan Zhang1,Yoke Khin Yap1
Michigan Technological University1,Stabilux Biosciences2
Nazmiye Yapici1,2,Estelle Chiari2,Xiuling Liu1,2,Catherine Pilon2,Daniel Gibbs2,Rodney Oakley2,Dongyan Zhang1,Yoke Khin Yap1
Michigan Technological University1,Stabilux Biosciences2
Cancer immunotherapy has revolutionized in recent years thanks to cutting-edge tools that have empowered researchers to understand adaptive immune systems better. Flow cytometry, for example, has become indispensable for immunological research and has evolved from a single to 50-color parameters. This multiplexing capability in flow cytometry is decisive for understanding complex tumor samples. However, there is a delicate balance between the quality and quantity of data. Spillover and auto-fluorescence have continued to limit multi-color measurement. Brighter dyes or fluorophores with high resolution are essential to ensure high-quality data.<br/>Introducing a breakthrough in our field, we present a new series of high-brightness fluorophores (HBFs) that promise to revolutionize rare antigen detection. Our NovoLux646, for instance, when conjugated with anti-human CD127, delivers a staining index (SI) of 107, a staggering 20X higher than that from Anti-CD 127-APC. NovoLux646 also outshines AlexaFluor647 in brightness. We also evaluated our violet NovoLux420 for CD 127 detection, achieving an SI as high as 222 from Anti-CD 127- NovoLux420, 16X brighter than cFluor420. These results hint at the potential of our HBFs to enable the detection of many more rare antigens, sparking a new era in immunological research. Details of our findings will be discussed at the conference.<br/><br/>We acknowledge the support from the National Science Foundation (Award number 1738466).